LFWD · Lifeward Ltd.
$7.10
-0.16 (-2.20%)
At close · Sep 3
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, the Company incurred a consolidated net loss of $22.3 million and, as of June 30, 2026, had an accumulated deficit in the total amount of $307.1 million. The Company's cash and cash equivalents as of June 30, 2026 totaled $9.4 million and the Company's negative operating cash flow for the six months ended June 30, 2026 was $9.7 million. The Company expects to continue to generate operating losses and negative operating cash flows in the foreseeable future and will require additional funding to support its planned operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern for at least 12 months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$20.56M
Shares
2.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.10
Open$7.27
Day$7.03–7.33
Since split$5.01–8.73
Avg vol 30d6K
Short int121K · 4.3% float · 17.8d
Short vol3%
Last earningsMay 15, 2026
DataFeb 2026–Sep 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on Feb 24, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Feb 24, 2026.
Up next
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$21.82M
Trailing 12 months
Net income (TTM)
−$30.83M
Trailing 12 months
Revenue growth YoY
+15.7%
Year over year
Operating margin
-104.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-83.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+198.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
4.3%
Latest settlement · 17.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.47
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−6%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
56%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+4%
trailing
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+13% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.28% of float · ▼ -0.5% MoM · 17.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−14%
Y/Y
Gross margin
38%
expanding
EPS growth
+57%
Y/Y
Free cash flow
$-16.8M
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−20%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Aug 15, 2024
Full year revenue
· full year 2024
$28M – $32M
Guided vs delivered
· last 1 settled
Full year revenue
full year 2024
guided $28M – $32M
$25.66M
Miss −14.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−6%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
56%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+13% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.28% of float · ▼ -0.5% MoM · 17.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 3-yr range
Price context
position in its range since split · 2026-02-24
Range low $5
Now $7 · 56%
Range high $9
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFWD
this stock
Lifeward Ltd.
|
$20.56M | — | -14.1% | — | 4.3% |
|
ABT
Abbott Laboratories
|
$192.64B | -13.2% | +5.7% | 31.0 | 1.2% |
|
SYK
Stryker Corp
|
$121.41B | -12.4% | +11.2% | 32.8 | 1.8% |
|
MDT
Medtronic plc
|
$118.37B | -3.1% | +8.4% | 24.8 | 1.1% |
|
BSX
Boston Scientific Corp
|
$70.10B | -50.8% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
9
- % held
- 1.1%
- Net QoQ
- +18.1K sh
- Top holder
- CITADEL ADVISORS LLC
Held
Float
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Feb 24, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFWD | -3.6% | -4.1% | +3.7% | -7.2% | — |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | -3.9% | -4.7% | -13.1% | -8.0% | — |